Biohaven (BHVN) Research & Development (2021 - 2026)

Biohaven has reported Research & Development for 6 years, with the latest figure at $103.8 million in Q1 2026.

• Quarterly Research & Development fell 44.65% year-over-year to $103.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $272.0 million (down 67.13% YoY) and the FY2025 annual result came in at $635.1 million, down 20.21% from the prior year.
• Research & Development improved to $103.8 million in Q1 2026 per BHVN's latest filing, from $12.0 million in the prior quarter.
• Over five years, Research & Development peaked at $314.8 million in Q2 2024 and troughed at $4.2 million in Q4 2022.
• A 5-year average of $113.7 million and a median of $103.8 million in 2026 frame the typical range for Research & Development.
• The sharpest annual moves came in 2023 and 2025: Research & Development soared 3075.81% in 2023, then tumbled 95.24% in 2025.
• Over 5 years, Research & Development stood at $4.2 million in 2022, then jumped by 3075.81% to $134.8 million in 2023, then advanced by 24.23% to $167.5 million in 2024, then plunged by 92.83% to $12.0 million in 2025, then soared by 765.22% to $103.8 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $103.8 million, $12.0 million, and $141.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.